Skip to content

BofA bullish on Retrophin, sees 56% upside

August 24, 2020

BofA analyst Scott Puckhaber has initiated coverage on Retrophin (RTRX +3.9%) with a Buy rating and $30 (56% upside) price target.

Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2 conference call.

He sees ~30% downside in the event if the trials are unsuccessful, but over 100% upside if both studies are winners.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: